DSM launches sale of anti-infectives maker DSP – sources

By Ludwig Burger and Arno Schuetze

FRANKFURT, – Dutch speciality chemicals company DSM has launched the sale of its anti-infectives unit DSM Sinochem Pharmaceuticals (DSP), a potential 640 million euro ($785 million) deal, as it seeks to streamline its portfolio, people close to the matter said.

DSP is a joint venture with China’s Sinochem, which acquired half of DSM’s pharma activities unit DAI in 2011.

DSM is working with Rothschild on the divestiture, the sources said. First-round bids were due earlier this week, and DSP is expected to attract the interest of private equity groups such as CVC, BC Partners, Bain, Charterhouse and SK Capital, one of the people said.

Sinochem has a right of first refusal but has signalled it will sell out, too, the people said.

DSP is expected to post earnings before interest, tax, depreciation and amortisation of roughly 80 million euros this year, and could be valued at at least 8 times that in a potential sale. Last year, its core profit was 73 million euros.

DSM is working towards a sale of a number of jointly owned ventures, also known as associates, which include businesses co-owned with U.S. biofuels maker POET or CVC, DSM finance chief Geraldine Matchett told analysts on an earnings call last month.

“And for DSP, it’s been a very solid year both in terms of growth and retaining the margin. So no clarifications on timing, except that directionally that is where we want to be heading with our associates,” she said.

DSM has been focusing on products such as vitamins and enzymes as well as fabrics and plastics used in cars, garments and construction, putting more commoditised and cyclical product lines into joint ventures with the view to eventually exiting those businesses.

DSM, Sinochem, Rothschild and the bidders declined to comment or were not immediately available for comment. ($1 = 0.8155 euros) (Additional reporting by Toby Sterling and Chen Aizhu Editing by Maria Sheahan)

  • Related Posts

    • Pharma
    • March 27, 2024
    • 105 views
    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Haryana has blacklisted Maiden Pharmaceuticals Ltd, based at Sonepat, for three years, thereby debarring the firm from participating in state tenders. All rate contracts issued to the firm have also…

    • Pharma
    • March 27, 2024
    • 69 views
    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    New Delhi: The Drugs Consultative Committee (DCC), the advisory committee formed by the Central government to advise the Central and state governments on matters that require uniform implementation of drug laws…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    Spurious drugs: Maiden Pharma blacklisted, all contracts cancelled

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    DCC Calls For Strict Implementation Of Revised Schedule M, State-Level Activities To Address AMR

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Sanofi, Cipla Join Hands To Expand Reach Of CNS Portfolio In India

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Cyberabad Police Seize 1 Kg Alprazolam, Arrest Three

    Lee Health develops natural capsule for effective Heart care

    Lee Health develops natural capsule for effective Heart care

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down

    Medical Shop Run By Twenty20 In Kizhakkambalam Asked To Shut Down